Stockscreener 앱 받기
4.07
2.52%
0.10
시간 외 거래:
4.07
Opthea Limited Adr 주식(OPT)의 최신 뉴스
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024 - The Manila Times
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024 - StockTitan
Opthea Advances Retinal Disease Treatments - TipRanks
Opthea Advances nAMD Treatment with Sozinibercept - TipRanks
Opthea Limited (NASDAQ:OPT) Shares Sold by Victory Capital Management Inc. - Defense World
EX-99.1 - SEC.gov
Opthea Advances Toward Sozinibercept Commercialization - TipRanks
Opthea’s Sozinibercept Eyes Breakthrough in AMD Therapy - TipRanks
FY2025 EPS Estimates for Opthea Limited Boosted by HC Wainwright (NASDAQ:OPT) - Defense World
Research Analysts Set Expectations for Opthea Limited’s FY2029 Earnings (NASDAQ:OPT) - Defense World
Opthea Prepares for Phase 3 Results with Leadership Revamp - TipRanks
Opthea (NASDAQ:OPT) Given New $12.00 Price Target at HC Wainwright - Defense World
Opthea Limited Showcases Innovations at Investor Conferences - TipRanks
Opthea Limited: Revenues Up, Losses Widen - TipRanks
Opthea Reports Full-Year Financial Results and Business Updates - Morningstar
Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024 - Morningstar
Opthea Limited Showcases at Ophthalmology Event - TipRanks
OPTOpthea Limited Latest Stock News & Market Updates - StockTitan
Opthea forms global medical advisory board for retinal diseases - Investing.com India
Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board - StockTitan
Opthea forms global medical advisory board for retinal diseases - Investing.com
Why Atturra, Bravura, Core Lithium, and Opthea shares are racing higher today - The Motley Fool
Opthea’s Sozinibercept Shows Promise for Wet AMD - TipRanks
Opthea Announces Publication on VEGF-C and D Signaling Pathways as Potential Targets for Treatment of Wet AMD - StockTitan
Opthea (NASDAQ:OPT) Shares Down 0.8% - Defense World
Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022 - The Globe and Mail
Opthea To Present at SVB Leerink Global Healthcare Conference - The Globe and Mail
Opthea strengthens its Board of Directors - Quantisnow
Optiva Wins Prestigious "Enterprise eSIM Solution of the Year" Award - GlobeNewswire Inc.
Optiva Inc. Announces Results of Annual and Special Meeting - GlobeNewswire Inc.
Opthea A$55.0m (US$36.9m¹) Retail Entitlement Offer Opens - GlobeNewswire Inc.
Opthea A$55.0m (US$36.9m¹) Retail Entitlement Offer Opens - Morningstar
Opthea raises $113.2 million to fund eye drug development - The Pharma Letter
Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹) - GlobeNewswire Inc.
Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹) - Morningstar
Opthea Announces Placement and Partially Underwritten Entitlement Offer to Raise up to Approximately A$227.3 million (US$150.0 million¹) - GlobeNewswire Inc.
Opthea To Present at Clinical Trials at the Summit Meeting - GlobeNewswire Inc.
Opthea LimitedADR (OPT) Price Target Increased by 9.06% to 5.95 - MSN
Market Insight: Opthea Limited ADR (OPT)'s Notable Drop, Closing at 3.00 – DWinneX - The Dwinnex
2 Stocks Under $10 Wall Street Says Are 'Strong Buys' - Barchart
Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD - GlobeNewswire Inc.
Opthea (NASDAQ:OPT) Shares Down 0.6% - Defense World
Optiva Inc. Reports First Quarter 2024 Financial Results - GlobeNewswire Inc.
Opthea Announces Upcoming Presentations at the Retina World Congress 2024 - GlobeNewswire Inc.
Optiva and GDi Announce Strategic Partnership to Deliver Integrated BSS and OSS Solutions - GlobeNewswire Inc.
Opthea Appoints John Han, PharmD, as VP Medical Affairs - GlobeNewswire Inc.
Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference By Investing.com - Investing.com South Africa
Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference - GlobeNewswire Inc.
Opthea Appoints Sujal Shah to the Board of Directors - GlobeNewswire Inc.
Opthea appoints new director and audit chair By Investing.com - Investing.com
11 Best ASX Stocks To Buy Now - Yahoo Finance
Opthea Limited completes enrollment for 1 of 2 Phase 3 sozinibercept (OPT-302) trials - Optometry Times
10 Best Australian Stocks To Buy - Yahoo Finance
Opthea Strengthens Team with Key Clinical and Regulatory Hires - BioSpace
AAO 2023: ShORe and COAST clinical trial updates from Opthea Limited - Ophthalmology Times Europe
AAO 2023: Updates on Opthea Limited ShORe and COAST clinical trials - Ophthalmology Times
ASRS 2023: Megan Baldwin, CEO of Opthea Limited, shares updates on sozinibercept - Ophthalmology Times Europe
ASRS 2023: Megan Baldwin, CEO of Opthea Limited shares updates on sozinibercept - Modern Retina
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends - Stockhead
Check Up: These 4 ASX healthcare stocks come with Strong Buy recommendations - Stockhead
Opthea Ltd ADR (OPT-Q) QuotePress Release - The Globe and Mail
OPTOpthea Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Biotech Company Opthea Aims To Raise $160M In US IPO - Yahoo Finance
Opthea Ltd (ASX: OPT) - The Motley Fool Australia
Opthea Limited ADR (CKDXY) OPT-302: Phase 1/2A wet AMD Trial UpdateSlideshow (NASDAQ:OPT) - Seeking Alpha
Opthea makes ophthalmology the focus - Finance News Network
0.05%
4.86%
자본화:
|
볼륨(24시간):